ALPN | Alpine Immune Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	64.97 - 65.00
52 Week Range	8.33 - 65.00
Beta	0.85
Implied Volatility	9.04%
IV Rank	1.15%
Day's Volume	4,288,333
Average Volume	2,371,991
Shares Outstanding	68,597,504
Market Cap	4,456,779,835
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-06-17

Valuation
Profitability
Growth
Health
P/E Ratio	-101.52
Forward P/E Ratio	N/A
EPS	-0.64
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	142
Country	USA
Website	ALPN

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN's peers: ARMP, LSTA

*Chart delayed

Analyzing fundamentals for ALPN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is strong. For more detailed analysis please see ALPN Fundamentals page.

Watching at ALPN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ALPN Technicals page.